SMARCA4突变诱导了瘤细胞内在缺陷的增强器景观和对免疫治疗的抗性
bioRxiv : the preprint server for biology
|July 1, 2024
概括
由于免疫细胞透率降低,SMARCA4缺乏的肺癌显示出免疫治疗反应不佳. 这是因为SMARCA4的损失会通过改变增强剂的可访问性和影响NF-κB活性来损害先天免疫基因表达.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 染色体生物学 染色体生物学
背景情况:
- 在癌症中发现了包括SMARCA4在内的SWI/SNF染色体重塑复杂元件的频繁变化.
- 在SMARCA4突变肺癌中,免疫疗法反应和预后不佳.
- 在SMARCA4突变肺癌中免疫疗法耐药性的潜在机制尚不清楚.
研究的目的:
- 研究SMARCA4缺陷肺癌中免疫疗法耐药性的机制基础.
- 阐明SMARCA4在调节瘤免疫微环境和基因表达中的作用.
- 探索SMARCA4,NF-κB和天生的免疫基因调节之间的相互作用.
主要方法:
- 使用免疫人性化,合成基因和基因工程小鼠模型的SMARCA4缺陷肺癌.
- 评估瘤免疫细胞透 (树突细胞,CD4+T细胞) 和对抗PD1免疫疗法的反应.
- 分析了基因表达,染色质可访问性 (ATAC-seq) 和转录因子结合 (SMARCA4,NF-κB ChIP-seq).
主要成果:
- 损失SMARCA4降低了抗PD1免疫疗法反应,与减少的树突细胞和CD4+T细胞透相关.
- 由于SMARCA4缺乏,导致STING,IL1β和炎症性细胞因子的下调,损害了免疫细胞的招募.
- SMARCA4损失重新编程了增强器景观,降低了天生的免疫基因位置的可访问性和丰富的NF-κB基因.
- SMARCA4和NF-κB共同占据STING和IL1β的增强剂,表明功能相互作用.
结论:
- 肺癌中SMARCA4缺陷通过破坏先天免疫基因表达,损害了抗PD1免疫疗法反应.
- 通过调节增强剂可访问性和NF-κB信号传递,SMARCA4调节免疫细胞透和抗瘤免疫.
- 这些发现提供了对免疫疗法耐药性的机制性见解,并建议对SMARCA4突变肺癌的潜在治疗点.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.4K
相关概念视频
Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Loss of Tumor Suppressor Gene Functions
4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K
